(Q50460765)

14 March 2018

title

A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTere. (English)

1 reference

14 March 2018

1 reference

1 reference

1 reference

Heloisa P Soares

1

1 reference

14 March 2018

Soley Bayraktar

2

1 reference

14 March 2018

Marcelo Blaya

3

1 reference

14 March 2018

Gilberto Lopes

4

1 reference

14 March 2018

Jaime Merchan

5

1 reference

14 March 2018

Jessica Macintyre

6

1 reference

14 March 2018

Carlos Mayo

7

1 reference

14 March 2018

Mark R Green

8

1 reference

14 March 2018

Orlando Silva

9

1 reference

14 March 2018

Joe Levi

10

1 reference

14 March 2018

Gail Walker

11

1 reference

14 March 2018

Caio M Rocha-Lima

12

1 reference

14 March 2018

publication date

23 February 2014

1 reference

14 March 2018

Cancer Chemotherapy and Pharmacology

published in

1 reference

14 March 2018

volume

73

1 reference

14 March 2018

issue

4

1 reference

14 March 2018

page(s)

839-845

1 reference

14 March 2018

https://scigraph.springernature.com/pub.10.1007/s00280-014-2414-z

exact match

0 references

cites work

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2414-Z

Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2414-Z

Taxanes and capecitabine in combination: rationale and clinical results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2414-Z

Capecitabine/Taxane combination therapy: evolving clinical utility in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2414-Z

Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2414-Z

A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2414-Z

Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2414-Z

Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2414-Z

Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2414-Z

RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2414-Z

Second-line chemotherapy with capecitabine (Xeloda) and docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2414-Z

Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2414-Z

10.1007/S00280-014-2414-Z

21 January 2018

Identifiers

DOI

1 reference

14 March 2018

1 reference

14 March 2018